Posted by Michael Wonder on 02 Apr 2025
Valneva’s chikungunya vaccine Ixchiq now authorised in EU for adolescents aged 12 and above
1 April 2025 - With this extension, Ixchiq, the first vaccine against the chikungunya virus, is now available for administration for individuals 12 years of age and older in the European Union.
Valneva today announced that the European Commission has granted marketing authorisation in Europe for Valneva’s single-dose vaccine, Ixchiq, for the prevention of disease caused by the chikungunya virus in individuals 12 years of age and older.
